Figure 6: C391 Reduces airway leukocyte recruitment in C57Bl/6 and BALB/c murine asthma models.
(A - D) Quantification of bronchoalveolar lavage fluid (BALF) cell counts in C57Bl/6 (A,B) and BALB/c (C, D ) as follows: (A, C ) total cells; (B, D) neutrophils, eosinophils, lymphocytes, and macrophages (with macrophage quantification shown on the right y- axis). A. alternatatreatment significantly increased total cell infiltration, and specifically the recruitment of eosinophils and lymphocytes in both mouse strains, as well as increased macrophages in BALB/c. Eosinophils and lymphocytes in C57Bl/6 were significantly attenuated in A. alternata exposed mice treated with C391, and lymphocytes and macrophages were significantly attenuated in A. alternata exposed mice treated with C391 in BALB/c. * Indicates significant difference between HBSS treated and A. alternata exposed mice; p ≤ 0.05 . # Indicates significant difference between A. alternata exposed mice and A. alternata exposed mice treated with C391; p ≤ 0.05.
Figure 7: C391 reduces airway hyperresponsiveness in a BALB/c murine asthma model.
BALB/c mice were given nasal instillations of treatment (HBSS control,A. alternata or A. alternata with C391) on days 0, 3, 6 and forced oscillation technique with methacholine challenge to measure lung resistance was performed on day 8. The percent change in maximum total airway resistance (Max Rrs) is reported. A. alternata treatment increases Max Rrs measurements over control. However, A. alternata treatment in the presence of C391 the Max Rrs are similar to control. n ≥ 4 for each treatment. * Indicates significant difference between HBSS treated and A. alternataexposed mice; p ≤ 0.05. # Indicates significant difference betweenA. alternata exposed mice and A. alterna ta exposed mice treated with C391; p ≤ 0.05.